transCampus Team, 
Strong long-lasting research collaborations have always been the core of transCampus. In order to enable project groups to take the next step, in 2025, transCampus funds three projects with good chances of acquiring third-party grants. All of them will further strengthen TUD’s expertise in the respective field:
Project 1 – Topic: Bipolar Disorder
Philipp Ritter from the department of psychiatry at the Faculty of Medicine was successful with his application on “Neural correlates of cognitive impairment in bipolar disorder”. He will work together with colleagues from the Institute of Psychology, Psychiatry and Neuroscience at King’s and the Institute of Acoustics and Speech Communication at TUD investigating the longitudinal trajectories and neural correlates of cognitive impairment in bipolar disorder.
Project 2 – Topic: Quantum Communcations
The project “Quantum Semantics for 6G” brings transCampus together with the Excellence Cluster CeTI. Assistant professor Riccardo Bassoli together with Osvaldo Simeone from the Centre for Intelligent Information Processing System at King’s aim at tackling some of the obstacles in semantic and goal-oriented communications. Despite investigating these research questions on quantum technology based solutions for the current excessive energy usage and other limitations, the team will also organize a second edition of the Summer School on “Quantum Communication Networks & Technologies”, planned for May 2025.
Project 3 – Topic: Leukaemia
The project “Deciphering metabolic and immune cell dysregulation in the leukaemic bone marrow niche” of Manja Wobus addresses an urgent clinical aspect. It focuses on the development of personalized therapies for patients with aggressive forms of acute myeloid leukaemia (AML), a fatal malignancy with limited treatment options and poor prognosis. The hematology team of the Department of Medicine I has a long standing collaboration with King’s College. This time, together with Lynn Quek from the Comprehensive Cancer Centre, they want to decode the “dysregulation of metabolic and immune cells” in order to combat leukemia more effectively.